Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
798 6 |
Ultima descărcare din IBN: 2023-09-19 17:24 |
Căutarea după subiecte similare conform CZU |
616.36+616.14]-036.12 (1) |
Patologia sistemului digestiv. Tulburări ale tubului alimentar (1732) |
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (975) |
SM ISO690:2012 GHEORGHE, Gina, ILIE, Mădălina, SOCEA, Bogdan, STĂNESCU, Alexandra Ana Maria, BRATU, Ovidiu Gabriel, IANCU, Mihaela Adela, OLARIU, Mihaela C., CIOBANU, Gheorghe, DIACONU, Camelia. Budd-Chiari syndrome . In: Archives of the Balkan Medical Union, 2019, nr. 2(54), pp. 345-350. ISSN 1584-9244. DOI: https://doi.org/10.31688/ABMU.2019.54.2.20 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Archives of the Balkan Medical Union | |
Numărul 2(54) / 2019 / ISSN 1584-9244 | |
|
|
DOI:https://doi.org/10.31688/ABMU.2019.54.2.20 | |
CZU: 616.36+616.14]-036.12 | |
Pag. 345-350 | |
Descarcă PDF | |
Rezumat | |
Budd-Chiari syndrome (BCS) is a rare disease characterized by obstruction of the hepatic veins, regardless of mechanism and degree, in the absence of heart disease, pericardial disease or sinusoidal obstructive syndrome. In relation to etiology, BCS is classified in primary BCS, when it is caused by an intravascular thrombosis, and secondary BCS, when the obstruction is due to extrinsic compression or tumor invasion. The positive diagnosis is based on patient’s medical history, clinical examination, and paraclinical investigations. The clinical picture is polymorphous. The most common signs and symptoms include fever, abdominal pain and abdominal tenderness on palpation, hepatomegaly, ascites, edema of the lower limbs, gastrointestinal bleeding and hepatic encephalopathy. Laboratory tests can detect the degree of liver injury, with decreased serum albumin, altered coagulation, hepatic cytolysis and cholestasis, while imaging investigations may reveal the venous obstruction. Regarding treatment, all patients with BCS are recommended systemic anticoagulation to reduce the risk of thrombus extension and prevention of further thrombotic episodes. Depending on patient’s individual characteristics, angiography with or without stent, thrombolysis, trans-jugular intrahepatic portosystemic shunt and liver transplant are to be considered. The syndrome’s severity and prognosis are dictated by the underlying disease, ranging from a possible curability to quick death. Copyright |
|
Cuvinte-cheie Anticoagulants, Budd-, Chiari syndrome, Hepatic vein obstruction, Trans-jugular intrahepatic portosystemic shunt |
|
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <identifier identifierType='DOI'>10.31688/ABMU.2019.54.2.20</identifier> <creators> <creator> <creatorName>Gheorghe, G.</creatorName> <affiliation>Spitalul Clinic de Urgență București, România</affiliation> </creator> <creator> <creatorName>Ilie, M.</creatorName> <affiliation>Spitalul Clinic de Urgență București, România</affiliation> </creator> <creator> <creatorName>Socea, B.</creatorName> <affiliation>Universitatea de Medicină şi Farmacie „Carol Davila“, România</affiliation> </creator> <creator> <creatorName>Stănescu, A.</creatorName> <affiliation>Universitatea de Medicină şi Farmacie „Carol Davila“, România</affiliation> </creator> <creator> <creatorName>Bratu, O.</creatorName> <affiliation>Universitatea de Medicină şi Farmacie „Carol Davila“, România</affiliation> </creator> <creator> <creatorName>Iancu, M.</creatorName> <affiliation>Universitatea de Medicină şi Farmacie „Carol Davila“, România</affiliation> </creator> <creator> <creatorName>Olariu, M.</creatorName> <affiliation>Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș", România</affiliation> </creator> <creator> <creatorName>Ciobanu, G.C.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Diaconu, C.</creatorName> <affiliation>Necunoscută, România, România</affiliation> </creator> </creators> <titles> <title xml:lang='en'>Budd-Chiari syndrome </title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2019</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1584-9244</relatedIdentifier> <subjects> <subject>Anticoagulants</subject> <subject>Budd-</subject> <subject>Chiari syndrome</subject> <subject>Hepatic vein obstruction</subject> <subject>Trans-jugular intrahepatic portosystemic shunt</subject> <subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616.36+616.14]-036.12</subject> </subjects> <dates> <date dateType='Issued'>2019-05-06</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Budd-Chiari syndrome (BCS) is a rare disease characterized by obstruction of the hepatic veins, regardless of mechanism and degree, in the absence of heart disease, pericardial disease or sinusoidal obstructive syndrome. In relation to etiology, BCS is classified in primary BCS, when it is caused by an intravascular thrombosis, and secondary BCS, when the obstruction is due to extrinsic compression or tumor invasion. The positive diagnosis is based on patient’s medical history, clinical examination, and paraclinical investigations. The clinical picture is polymorphous. The most common signs and symptoms include fever, abdominal pain and abdominal tenderness on palpation, hepatomegaly, ascites, edema of the lower limbs, gastrointestinal bleeding and hepatic encephalopathy. Laboratory tests can detect the degree of liver injury, with decreased serum albumin, altered coagulation, hepatic cytolysis and cholestasis, while imaging investigations may reveal the venous obstruction. Regarding treatment, all patients with BCS are recommended systemic anticoagulation to reduce the risk of thrombus extension and prevention of further thrombotic episodes. Depending on patient’s individual characteristics, angiography with or without stent, thrombolysis, trans-jugular intrahepatic portosystemic shunt and liver transplant are to be considered. The syndrome’s severity and prognosis are dictated by the underlying disease, ranging from a possible curability to quick death. Copyright</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>